Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Albert Enz"'
Autor:
Ulrike Lorch, Monika Büche, Steve Maton, Silke Appel-Dingemanse, Albert Enz, Cyriaque Sagan, Greg Sedek, Gilbert Lefèvre
Publikováno v:
The Journal of Clinical Pharmacology. 49:430-443
The pharmacokinetics and pharmacodynamics of rivastigmine were compared in Japanese and white healthy participants who were given ascending single doses of the novel rivastigmine transdermal patch. Rivastigmine patch strengths were 4.6 mg/24 h (5 cm2
Publikováno v:
European Journal of Pharmacology. 572:142-150
The effects of (−)-N 1 phenethyl-norcymserine (PEC, 5 mk/kg, i.p.) on acetylcholine release and cholinesterase activity in the rat cerebral cortex were compared with those of donepezil (1 mg/kg, i.p.), a selective acetylcholinesterase inhibitor, an
Autor:
Annick Vassout, Dieter Sorg, Daniel Langenegger, Paul Pfäffli, Conrad Gentsch, Konstanze Hurth, Troxler Thomas J, Philipp Floersheim, Neumann Peter, Daniel Hoyer, Albert Enz, Swoboda Robert
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:3988-3991
The SAR of over 50 derivatives of octahydrobenzo[g]quinoline (obeline)-type somatostatin sst1 receptor antagonist 1 is presented, focusing on the modification of its arylpiperazine moiety. Sst1 affinities in this series cover a range of five orders o
Autor:
Gilbert Lefèvre, Françoise Pommier, Silke Appel-Dingemanse, Heinz Schmidli, M. T. Leibowitz, Albert Enz, Steve Maton, S. S. Jhee, Hsun-Lun Aaron Huang, Larry Ereshefsky, Greg Sedek
Publikováno v:
Clinical Pharmacology & Therapeutics. 83:106-114
A transdermal patch has been developed for the cholinesterase inhibitor rivastigmine. This study investigated the pharmacokinetics and pharmacodynamics of rivastigmine and NAP226-90, and compared drug exposure between patch and capsule administration
Autor:
HANS FLIRI, GOETZ BAUMANN, ALBERT ENZ, JUERG KALLEN, MARCEL LUYTEN, VINCENT MIKOL, RAO MOVVA, VALERIE QUESNIAUX, MAX SCHREIER, MALCOLM WALKINSHAW, ROLAND WENGER, GERHARD ZENKE, MAURO ZURINI
Publikováno v:
Annals of the New York Academy of Sciences. 696:47-53
Cyclosporin A (Sandimmun) achieves immunosuppressive activity by complex formation with cyclophilin and subsequent binding of the binary complex to and inhibiting protein phosphatase 2B (calcineurin). Complexes of nonimmunosuppressive cyclophilin bin
Autor:
Willy Kinzy, Ulf Neumann, Markus Stoeckli, Albert Enz, Hans-Ulrich Gremlich, Matthias Staufenbiel, Anne-Lise Jaton, Karl-Heinz Wiederhold, Peter Frey, Martin Hintersteiner, Markus Rudin, Rainer Kneuer
Publikováno v:
Nature Biotechnology. 23:577-583
As Alzheimer's disease pathogenesis is associated with the formation of insoluble aggregates of amyloid beta-peptide, approaches allowing the direct, noninvasive visualization of plaque growth in vivo would be beneficial for biomedical research. Here
Publikováno v:
Dementia and Geriatric Cognitive Disorders. 19:18-23
Alzheimer’s disease is a neurodegenerative disorder that affects the cholinergic, glutamatergic and monoaminergic systems in the neocortex and hippocampus. Today, the major pharmacological treatment involves the use of acetylcholinesterase inhibito
Autor:
Albert Enz, Conrad Gentsch
Publikováno v:
Neuropharmacology. 47:408-413
Rivastigmine, a cholinesterase inhibitor, is successfully used for the symptomatic therapy of Alzheimer's disease (AD) in the clinic. The drug has a very low potential for drug-drug interactions, as has been demonstrated within large clinical trials.
Publikováno v:
Biomedical Chromatography. 18:160-166
A simple and sensitive reversed-phase liquid chromatography coupled with electrospray-mass spectrometry was developed and validated for the simultaneous determination of rivastigmine, a cholinesterase inhibitor, and its major metabolite NAP 226-90 in
Autor:
Luca Bondolfi, Michelle Pfeifer, Peter H. Kelly, Martina Stalder, Sonia Boncristiano, Mathias Jucker, Michael E. Calhoun, Matthias Staufenbiel, Amie L. Phinney, Bernd Sommer, Dorothee Abramowski, Albert Enz, Christine Sturchler-Pierrat
Publikováno v:
The Journal of Neuroscience. 22:3234-3243
Alzheimer's Disease (AD) is a neurodegenerative disorder that is characterized by extracellular deposits of amyloid-beta peptide (Abeta) and a severe depletion of the cholinergic system, although the relationship between these two events is poorly un